Location: Virtual
Start Date: Nov 04, 2025
Start Time: 16:00 CET | 07:00 PST | 10:00 EST | 15:00 BST
Type of Event: Webinars
Attendees:

About the Webinar

Tuesday 4th November 2025

7am PST | 10am EST | 3pm GMT | 4pm CET 


Join our exclusive webinar to see how Evotec’s innovative chemoproteomics strategies and high-throughput mass spectrometry platforms are accelerating covalent hit identification and validation. 

Attend this webinar to explore the latest innovations in covalent drug discovery including:

  • covalent inhibitors positioning and their unique benefits in modern drug discovery
  • how high throughput mass spectrometry accelerates covalent hit ID
  • site specific analysis using peptide mapping and intact protein mass spectrometry
  • advanced chemoproteomics strategies for hit validation 
     

Meet the Speakers

Julien Parra Ph D

Julien Parra PhD

Senior Research Scientist, High Throughput Biology & Screening

Latest update: December 2025

Biography

Currently serving as a senior research scientist in the high-throughput biology and screening team at Evotec in Toulouse, Dr. Julien Parra is a highly experienced mass spectrometry specialist with over a decade of experience in analytical chemistry, proteomics and structural biology. Julien earned his PhD in analytical chemistry from the Université Évry Paris-Saclay and later joined the Institute of Pharmacology and Structural Biology as a postdoctoral researcher. His work is characterized by a deep understanding of protein chemistry, a strong command of mass spectrometry instrumentation and a passion for translating complex data into biological insights.

Violette Gautier Ph D

Violette Gautier PhD

Research Scientist, Proteomics

Latest update: December 2025

Biography

Dr. Violette Gautier is a proteomics research scientist with over fifteen years of experience in proteomics, including more than nine years in the pharmaceutical industry. At Evotec, she specializes in chemoproteomics approaches such as activity-based protein profiling and cysteine proteomics profiling. She contributes to covalent drug discovery programs by developing and applying chemoproteomic workflows that support key stages of compound progression - from target identification and ligand library screening to cellular target engagement and selectivity profiling. Violette earned her PhD in structural and functional biology from Toulouse III University and completed her postdoctoral research at Utrecht University. Both focused on advanced proteomic strategies to investigate protein networks, cellular mechanisms and post-translational modifications.